Bevacizumab Biosimilar IBI305 plus sintilimab — Competitive Intelligence Brief

Bevacizumab Biosimilar IBI305 plus sintilimab (Bevacizumab Biosimilar IBI305 plus sintilimab) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PD-1 inhibitor and anti-VEGF monoclonal antibody. Area: Oncology.

phase 2 PD-1 inhibitor and anti-VEGF monoclonal antibody PD-1 and VEGF-A Oncology Small molecule

Target snapshot

Bevacizumab Biosimilar IBI305 plus sintilimab (Bevacizumab Biosimilar IBI305 plus sintilimab) — Ze-yang Ding, MD. Bevacizumab Biosimilar IBI305 is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), while sintilimab is a PD-1 inhibitor that blocks the PD-1/PD-L1 interaction.

Comparator set

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Bevacizumab Biosimilar IBI305 plus sintilimab TARGET	Bevacizumab Biosimilar IBI305 plus sintilimab	Ze-yang Ding, MD	phase 2	PD-1 inhibitor and anti-VEGF monoclonal antibody	PD-1 and VEGF-A

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PD-1 inhibitor and anti-VEGF monoclonal antibody class)

1. Ze-yang Ding, MD · 1 drug in this class